

## Company profile

Fact Sheet (Status: May 17, 2012)

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.

## Management board

- Marcus Kirchhoff (C)
- Dr. Robert Hannemann

## Supervisory board

- Prof. Dr. Heinz-Otto Peitgen (Chairman)
- Dr. Jens J. Kruse
- Peter Kuhlmann-Lehmkuhle

## Share chart



## Financial calendar

Aug 30, 2010	Analysts' Conference
Apr 19, 2011	Publication of Annual Report
May 30, 2011	Publication of Q1 Report
Jun 15, 2011	Annual General Meeting
Aug 29, 2011	Publication of Q2 Report
Aug 29, 2011	Analysts' Conference
Nov 21, 2011	Publication of Q3 Report
Nov 23, 2011	Analysts' Conference
Apr 24, 2012	Publication of Annual Report
May 30, 2012	Publication of Q1 Report
Jun 12, 2012	Annual General Meeting
Aug 27, 2012	Publication of Q2 Report
Nov 12, 2012	Analysts' Conference
Nov 12, 2012	Publication of Q3 Report

## Shareholder structure

19.5%	Dr. Carl J.G. Evertsz	3.3%	Axxion S.A. Luxembourg
19.5%	Prof. Dr. Heinz-Otto Peitgen	3.0%	Peter Kuhlmann-Lehmkuhle, Bremen
16.5%	Dr. Hartmut Jürgens	5.4%	Treasury Shares
10.9%	Fortelus Special Situations Master Fund Ltd., London	16.7%	Other Freefloat
5.2%	PEN GmbH		

## Stock fundamentals

ISIN	DE000A0LBFE4
WKN	A0LBFE
Share type	Ordinary
Reuters Code	M3VG.DE
Bloomberg Code	M3V@GR
Ticker	M3V

Branch	Software/Medical Technology
Country	Germany
Index	-
Segment	Prime Standard
Last Dividend	-
No. of shares	1,820,000

Stock exchanges	Prime Standard (Regulated Market); open market: Berlin, Düsseldorf, Munich, Stuttgart
Rating	-

## Key figures

Annual figures	2005	2006	2007	2008	2009	2010	2011
<b>in € k (IFRS)</b>							
Revenues	3,953	8,342	7,892	10,844	13,869	14,291	13,678
Income from the capitalization of development expenses	0	0	0	2,242	2,308	2,786	2,397
Other operating income	184	900	764	1,062	1,828	1,140	1,147
Cost of materials/cost of services purchased	(162)	(427)	(650)	(667)	(459)	(690)	(712)
Staff costs	(1,397)	(2,325)	(4,202)	(8)	(9,799)	(10,382)	(9,173)
Other operation expenses	(919)	(1,496)	(2,555)	(4,054)	(3,273)	(3,692)	(2,921)
EBITDA	1,659	4,994	1,249	1,757	4,474	3,453	4,416
Depreciation and amortization	(187)	(253)	(443)	(1,092)	(2,841)	(8,880)	(6,058)
EBIT	1,472	4,741	806	665	1,633	(5,427)	(1,642)
Interest income	7	66	198	1,052	598	389	122
Interest expenses	(392)	(330)	(137)	(321)	(996)	(712)	(346)
Net financial result	(397)	(264)	(319)	2,041	(465)	(180)	(1,273)
EBT	1,075	4,477	487	2,706	1,168	(5,607)	(2,915)
Income tax expense	(88)	(1,542)	(355)	(592)	(770)	(2,742)	(1,177)
Consolidated net profit for the period	987	2,935	132	2,114	398	(8,349)	(4,092)
Earnings per share in €			0.17	1.21	0.23	(4.89)	(2.38)
Intangible assets	324	389	1,388	26,876	27,095	22,001	18,921
Fixed assets	122	287	398	1,414	1,191	926	685
Cash & Cash equivalents	2,024	5,428	28,471	15,257	7,718	5,621	6,076
Securities	0	0	0	5	7,375	2,541	1,430
Equity Capital	(282)	2,653	30,769	32,611	32,607	24,789	20,729
Non-current liabilities	2,185	566	689	13,944	7,025	5,853	4,238
Current liabilities	2,194	5,884	4,117	13,029	11,323	8,143	7,582
Total assets	4,097	9,103	35,575	59,584	50,955	38,785	32,549
Employees (full-time equivalents)	26	26	38	138	186	178	146
Cash flow from operating activities	1,760	4,595	(2,468)	2,908	3,071	4,950	5,107

Quarterly figures	2010			2011		
	Q2	Q3	Q4	Q1	Q2	Q3
<b>in € k (IFRS)</b>						
Revenues	3,603	3,582	3,388	3,718	2,970	3,413
Income from the capitalization of development expenses	700	961	623	782	527	510
Other operating income	329	420	123	195	164	220
Cost of materials/cost of services purchased	(174)	(125)	(286)	(45)	(63)	(102)
Staff costs	(2,677)	(2,525)	(2,396)	(2,510)	(2,341)	(2,122)
Other operation expenses	(838)	(768)	(1,469)	(727)	(704)	(552)
EBITDA	943	1,545	(17)	1,413	553	1,367
Depreciation and amortization	(942)	(862)	(6,244)	(904)	(880)	(884)
Impairments	0	0	(5,327)	0	0	0
EBIT	1	683	(6,261)	509	(327)	483
Net interest expense	(70)	(78)	(93)	(75)	(71)	(63)
Net financial result	(117)	203	(107)	(286)	(331)	179
thereof: profit share from associated companies	(17)	(72)	87	(42)	(96)	21
EBT	(116)	886	(6,368)	223	(658)	662
Income tax expense	(386)	(581)	(1,722)	(413)	(324)	(413)
Consolidated net profit for the period	(502)	305	(8,090)	(190)	(982)	249
Earnings per share in €	(0)	0	(4.74)	(0.11)	(0.57)	0
Cash and cash equivalents	7,406	7,630	5,621	8,381	7,806	7,922
Securities	6,760	6,037	2,541	2,048	1,734	1,720

## MeVis Medical Solutions AG

MeVis Medical Solutions AG  
Universitaetsallee 29  
28359 Bremen  
Germany

Tel: +49 421 22495 0  
Fax: +49 421 22495 11  
office.mms@mevis.de  
http://www.mevis.de

## Investor Relations

**Investor Relations Contact**  
ir@mevis.de  
Tel.: +49 421 22495 0  
Fax: +49 421 22495 11